InnoCare Pharma’s Post

📢US Bill Threatens China's Biotech Industry 📰 The shares of WuXi Bio, a Chinese biotech firm, have dropped after the US introduced a bill targeting China's biotech industry. The bill aims to protect US biotech companies and their intellectual property from theft and forced technology transfer. This could have significant implications for China's biotech sector. #BioprocessUpdates #WuXiBio #USBIOSecureBill #ChinaBiotech #IntellectualProperty #TechnologyTransfer #BiotechIndustry #USProtection #USCompanies #ChineseFirm #SharesDrop #USBill #Implications #BiotechSector #Theft #WuXi #China ▷ Read the full article here: 📎 https://lnkd.in/daG6Qepy

Swedish biotech/CRO/CDMO companies - here is a great change to increase your business activities in industry leader Switzerland 🇨🇭 Shall we organize a Swedish/Nordic delegation to Swiss Biotech Day? Swiss Biotech Association SwedenBIO Business Sweden Gustav Henriksson Business Finland Medicon Valley Alliance

Standing at the new starting point of IFEAT, Cixiang Pharmtech knows that the road ahead is long, but the line is coming; If we don't stop, the future is promising. We will adhere to the core concept of "science and technology lead health, innovation achieve the future", continue to increase investment in research and development, optimize product structure, and enhance technological innovation capabilities. At the same time, we actively learn from the advanced experience and management mode of IFEAT member units, constantly improve our core competitiveness, and contribute wisdom and strength to the progress of the industry. We firmly believe that through the broad platform of IFEAT, Cixiang will be able to grasp the pulse of the market faster, gain insight into industry trends, and work together with global peers to create brilliance. In the future journey, Cixiang Pharmtech will be more open mind, more firm pace, toward the goal of becoming the industry benchmark, write a more brilliant chapter!

Just Announced: BioCentury Inc. and The BayHelix Group will bring the 4th East-West Biopharma Summit back to Singapore in March 2025. Why #Singapore?     ➤ Government support: After 20 years of government-led investment in science, talent, and infrastructure, the stage is set for the #lifesciences industry to carry the ball forward. ➤ Top investors: With #VC money pouring in, new investment and partnerships opportunities are emerging. ➤ Asia hub: As the gateway to Asia, Singapore is the place to meet industry leaders from an emerging Arc of Innovation including Japan, Korea, China, Australia, India, and Southeast Asia.    Please join us for this exclusive event designed for VCs and #biopharma decision-makers. Register for #BioCenturyEastWest with early bird rates: https://loom.ly/WqidFHU

According to OECD - OCDE data, Lithuania is one of the top global performers in biotech, boasting 20% Biotechnology R&D intensity. Among 26 countries assessed, it secures the third spot, behind leaders Belgium and Switzerland 🌍 This score indicates biotech prioritization within the economic landscape and showcases a strong focus on innovation and international competitiveness, highlighting Lithuania's ambition to become a key player in the European biotech arena. "R&D intensity figures guide us on innovation hotspots, sparking a conversation about biotechnology's future potential on a global scale.", says Daiva Radzevičiūtė, CEO of Biogroup Baltics. More information about the case: Labiotech.eu article: https://lnkd.in/es3xTTTf  OECD’s data: https://lnkd.in/dKK4v9QW #Biotechnology #Innovation #LifeScience 

New Policy Brief! 📑 IIPP PhD Researcher Giovanni Tagliani presents the case of bioproduction targeting in Thailand, charting the policy origins and how policy evolution has adapted along phases of innovation and technological sophistication. Read it here ➡️ https://lnkd.in/ez4TtxRy

Attention all healthcare investors! QIC is proud to introduce the Taiwan Healthcare Monthly Dose – a bespoke investment newsletter catering to those interested in the healthcare, biotech, pharma, and Medtech sectors. Each month, we will provide the latest market insights, updates on Taiwan and global news events, and our expert commentary. If there are specific topics or information you would like to see covered in our Monthly Dose, please don't hesitate to let us know. We are committed to delivering the content that matters most to you. Additionally, if you have any feedback or would like to subscribe to every issue of the Taiwan Healthcare Monthly Dose, please feel free to reach out to us! #QIC #Taiwan #BioTech #Healthcare #Newsletter #InvestmentInsights #TaiwanBusiness #MonthlyPublication #LaunchAlert 🚀📊  Kuan-Jan W. Peter Kurz

🎆Exciting news to kick-start 2024! Lithuania just clinched the 3rd spot among OECD countries for R&D intensity in biotech, alongside global leaders like the US, Belgium, and Switzerland. With every year our journey towards becoming a regional life sciences powerhouse is gaining momentum. Looking ahead, plenty of ambitious plans are waiting to be announced, creating an upbeat atmosphere within the industry and reflecting the collaborative spirit driving innovation. For a deeper dive into our 🧬ecosystem, check out the detailed article in the comments below. Let's keep the momentum going! 🚀 #LifeSciences #biotech #lithuania

Introducing the members of the European Biosolutions Coalition: The Federation of Austrian Industries (IV)   Federation of Austrian Industries is a voluntary and independent representation of the interests of the Austrian industry and its related sectors. Austria IV is currently representing over 4,500 members across manufacturing, credit, insurance, infrastructure, and industry-oriented services in Austria and Europe.   Why did Austria IV join the European Biosolutions Coalition? Director-General, Mr. Christoph Neumayer, puts it like this: “We are delighted to take part in this timely initiative of our Danish colleagues to advance the regulatory and financial framework for bioindustrial solutions and the biotechnology sector. Innovative industrial products and processes in these fields will facilitate our decarbonization efforts and create new markets along the way. Europe can and should position itself as biosolutions leader.”   Did you know? That the 275 leading companies based in Austria currently spend a whopping 5.3 billion euros a year on innovation, which means they account for 41% of the total R&D expenditure in Austria.   #biosolutions #greentransition #sustainability #innovation #eu

🔬🤝 We’re pleased to partner NSG BioLabs on its fourth facility in the Geneo life sciences and innovation cluster at #SingaporeSciencePark. Combining CapitaLand’s real estate expertise with NSG BioLabs’ deep experience and networks in the biotech ecosystem, this collaboration will create Southeast Asia’s largest co-working laboratory space at approximately 35,000 square feet (sq ft) and will bring NSG BioLab’s total size to more than 70,000 sq ft. This partnership marks an exciting development for Geneo as we introduce #biotech co-working lab space to support the growth of the #lifesciences and deep tech companies in Singapore. From developing pioneering products to fostering industry engagements, Geneo is set to become a key driver of #innovation and collaboration in Singapore's thriving biotech ecosystem. Jointly developed by #CapitaLandDevelopment and CapitaLand Ascendas REIT (#CLAR), Geneo comprises three properties with five state-of-the-art buildings that will offer about 1.94 million sq ft of gross floor area with work-live-play elements when fully completed in 2025. Peet Mun Chew Daphne Teo